Literature DB >> 1765105

Effect of the amine non-leaving group on the structure and stability of DNA complexes with cis-[Pt(R-NH2)2(NO3)2].

J L Butour1, P Alvinerie, J P Souchard, P Colson, C Houssier, N P Johnson.   

Abstract

The antitumor compound cis-[Pt(NH3)2Cl2] (cisplatin), conserves two ammine ligands during the reaction with its cellular target DNA. Modifications of these non-leaving groups change the antineoplastic properties of this compound and its genotoxic effects. It is therefore of interest to determine the influence of non-leaving groups on the structure and stability of DNA in vitro. We have investigated platinum-DNA adducts formed by cis-[Pt(R-NH2)2(NO3)2] (where R-NH2 = NH3, methylamine, cyclobutylamine, cyclopentylamine and cyclohexylamine) as a function of DNA binding. All compounds quantitatively reacted with DNA in less than 1 h at 37 degrees C. They formed bifunctional adducts with adjacent nucleotides judging from the displacement of the intercalating molecule ethidium bromide, ultraviolet absorption spectroscopy and circular dichroism. Substitution of a H on the NH3 ligand by alkyl groups dramatically destabilized the platinum-DNA complex. Thermal stability decreased progressively with an increasing number of carbon atoms, delta tm = -4.4 degrees C for 3 cyclohexylamine-platinum-DNA adducts/1000 nucleotides, conditions where cisplatin had no effect. DNA adducts with cyclobutylamine and cyclohexylamine ligands inhibited the hydrolysis of platinum-DNA complexes by S1 nuclease. Km for the digestion of DNA containing these lesions was 2.3 times greater than for cisplatin, indicating steric inhibition of enzyme-substrate complex formation. These results show that the non-leaving groups of substituted cis-Pt(II) compounds may destabilize DNA and interfere with protein-DNA interactions. These perturbations may have consequences for the genotoxic and antitumor activities of platinum compounds.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1765105     DOI: 10.1111/j.1432-1033.1991.tb16458.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  5 in total

1.  DNA adducts of antitumor trans-[PtCl2 (E-imino ether)2].

Authors:  V Brabec; O Vrána; O Nováková; V Kleinwächter; F P Intini; M Coluccia; G Natile
Journal:  Nucleic Acids Res       Date:  1996-01-15       Impact factor: 16.971

2.  Synthesis and characterization of CREKA-conjugated iron oxide nanoparticles for hyperthermia applications.

Authors:  Anastasia M Kruse; Samantha A Meenach; Kimberly W Anderson; J Zach Hilt
Journal:  Acta Biomater       Date:  2014-01-31       Impact factor: 8.947

3.  Antitumor carboplatin is more toxic in tumor cells when photoactivated: enhanced DNA binding.

Authors:  Jarmila Mlcouskova; Jana Stepankova; Viktor Brabec
Journal:  J Biol Inorg Chem       Date:  2012-05-26       Impact factor: 3.358

4.  Conformation and recognition of DNA modified by a new antitumor dinuclear PtII complex resistant to decomposition by sulfur nucleophiles.

Authors:  Lenka Zerzankova; Tereza Suchankova; Oldrich Vrana; Nicholas P Farrell; Viktor Brabec; Jana Kasparkova
Journal:  Biochem Pharmacol       Date:  2009-08-12       Impact factor: 5.858

5.  Potentiating effect of UVA irradiation on anticancer activity of Carboplatin derivatives involving 7-azaindoles.

Authors:  Pavel Štarha; Zdeněk Trávníček; Zdeněk Dvořák; Tereza Radošová-Muchová; Jitka Prachařová; Ján Vančo; Jana Kašpárková
Journal:  PLoS One       Date:  2015-04-15       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.